As to the IMbark data end points (reduced liver size) may still take time to confirm by Janssen. If patient survivability is improved through increased CR's & PR's as demo'd in the Mayo trial, they are not trial end points so perhaps this observation may not be under the Janssen shroud of darkness.
Yup, l couldn't bare to see another bear raid in my pantry. 2 years of this #$%$ has left me with bare cupboards.
How's that Need more ham upgrade working out for you Joko?
But then again he could take a year to book the payment like with the upfront payment from J&J. He's getting paid $1.3 mil to be a lackey for Janssen ultimate goal. Good compensation when you can get it.
Annie you have been dead wrong on every short squeeze threat potential to the hedgefund shorts since you've started posting here. About the same time our lucky charm vanished.
What makes Monday any different than before. Had Gern been expecting new interim data released the up coming ASCO presentation he would have said to expect something. He specifically said no interim data updates till end of last Q4 2016. I expected a milestone payment with a new dosing trial to be the next catalyst. But that must be registered on the govt. trial website bfr hand. He did point to this clue.
Geron has to apply first for breakthrough Therapy Designation on Imet. They have yet to do so. You may still have another decade of waiting.
That website is heavily used by ostriches looking to burry their collective heads in the sand.
Since when does Gerny ever appear in step?
If you look to the options one might expect good trial news, but without new data updates no one will be able to confirm success. Ocam's razor
As on date is June 6
Huge option vol. in the $3-$5 call range. But as demonstrated bfr. The hedgefund gaming this stock pulled that hedge dump last and the previous 2 months bfr.
Sweet cheeks your right I just sold out about 2wks ago at a substantial loss but you my psycho are indeed the devil's right hand handle.
Only fools fall in love with a stock that never moves up and holds it's gains. June 13, 2014 SP was $3.02 Today two years later it'll be trading at less than that by Monday.
This kind of thing is seen time & time again by large pharma. Gern will be stood up twice at the alter now
Just like now shareholders are still waiting for a milestone payment from it's current partner. Too bad we have a CEO who could care less about the company shareholders and only seeks self compensation allowing the company's intellectual assets to be taken by the big guys for virtually nothing.
After hours vol was up $123K @$3.07 4.4K @$3.20
Maybe someone likes a rabbit act.